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A Survey on Cellular and Engineered
Tissue Therapies in Europe in 2008
Ivan Martin, Ph.D.,1,* Helen Baldomero,2,* Alan Tyndall, M.D.,3,*
Dietger Niederwieser, M.D.,4,* and Alois Gratwohl, M.D.2,*
Cellular therapy is an evolving investigational treatment modality in regenerative medicine, but little published
information is available on its current use. Starting from the established European group for Blood and Marrow
Transplantation activity survey on hematopoietic stem cell transplantation, a joint committee of four major sci-
entific organizations made a coordinated attempt to collect detailed information in Europe for the year 2008.
Thirty-three teams from 16 countries reported data on 656 patients to a ‘‘novel cellular therapy’’ survey, which
were combined to additional 384 records reported to the standard European group for Blood and Marrow
Transplantation survey. Indications were cardiovascular (29%; 100% autologous), musculoskeletal (18%; 97%
autologous), neurological (9%; 39% autologous), epithelial/parenchymal (9%; 18% autologous), autoimmune
diseases (12%; 77% autologous), or graft-versus-host disease (23%; 13% autologous). Reported cell types were
hematopoietic stem cells (39%), mesenchymal stromal cells (47%), chondrocytes (5%), keratinocytes (7%), myo-
blasts (2%), and others (1%). In 51% of the grafts, cells were delivered after expansion; in 4% of the cases, cells were
transduced. Cells were delivered intravenously (31%), intraorgan (45%), on a membrane or gel (14%), or using
three-dimensional scaffolds (10%). This data collection platform is expected to capture and foresee trends for novel
cellular therapies in Europe, and warrants further consolidation and extension.
Introduction
Stem cell therapies are defined as ‘‘treatment in whichstem cells are induced to differentiate into the cell type
required to repair damaged or destroyed cells or tissues’’
(www.stemcells.nih.gov/info/glossary.asp). The most famil-
iar example is hematopoietic stem cell (HSC) transplantation.
However, more recently, stem, progenitor, and differentiated
cells of various lineages are increasingly being employed as
‘‘novel cellular therapy,’’ exploiting not just their ability to
differentiate and repair, but also their capacity to home to
damaged tissues and perform local paracrine healing and
protective functions. As many disparate specialty groups are
now involved, it is difficult to obtain an overview of these
activities.
The annual activity report by the European Group for
Blood and Marrow Transplantation (EBMT) has become an
established instrument to observe trends and to monitor
changes in the use of HSC transplants for the treatment of
hematologic disorders in Europe.1–5 The activity survey does
not provide any data on outcome, on the age or sex of patients,
or on their pre- and posttransplant therapy. The goal of the
data collection is the rapid dissemination of the status quo in
the field of HSC therapies, to provide a formal basis for patient
counseling and health care planning. Long-term analyses
provided evidence that the survey can foresee trends with
high predictability and very rapidly. In the past years, for
example, the activity survey was able to capture the increas-
ing use of cord blood as a stem cell source, the change from
bone marrow to peripheral blood, or the utilization and in-
tegration of unrelated donor transplants.6
In 2007, the EBMT report included for the first time infor-
mation on treatments based on mesenchymal stromal cells or
on HSC for nonhematological indications.6 The collected in-
formation confirmed the importance of mesenchymal stromal
cell grafts7 and the use of HSC for cardiovascular and neu-
rological disorders, as well as for tissue repair.8–10 However,
the structure of the distributed form did not allow capturing
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several relevant features of the novel cellular therapy trans-
plants (e.g., those related to the cell processing and delivery
mode). Moreover, since those grafts are frequently performed
outside the traditional hematology units, it became apparent
that involvement of additional working groupswas necessary
to increase the relevance of the program.
In 2008, the European sections of the Tissue Engineering
and Regenerative Medicine International Society (TERMIS-
EU), of the International Society of Cellular Therapy (ISCT-
Europe), and of the International Cartilage Repair Society
(ICRS) have for the first time coordinated a joint initiativewith
the EBMT and the European League Against Rheumatism
(EULAR) to establish a comprehensive, quantitative map of
patients being treated in Europe with specific cell types, sor-
ted by the cell processes, and delivery modes used. In this
article, we report the results of the first survey for the activity
in 2008 and provide a perspective for a further extended and
consolidated program for the years to come.
Patients and Methods
Data collection and validation
Participating teams were requested to report their data for
2008 by indication, cell type and source, donor type, proces-
sing method, and delivery mode. The survey followed the
traditional principles of the EBMT, concentrating on numbers
of patients with a first cellular therapy. For EBMT teams not
using the full questionnaire, information on cellular therapies
was limited to numbers of HSC for nonhematopoietic use,
mesenchymal stromal cell–based therapies (later identified to
be exclusively related to treatment of graft-versus-host dis-
ease), and donor type. Questionnaires were collected by paper
forms or electronically. Quality control measures, for EBMT
members only, included several established independent
systems: confirmation of validity of the entered data by the
reporting team, selective comparison of the survey data with
MED-A data sets in the EBMT ProMISE data system, cross
checking with the National Registries, and onsite visits of
selected teams. No quality control system could be applied for
the non-EBMT reporting teams yet.
Teams
Members of the 4 participating societies from 47 countries
(39 European and 8 affiliated countries) were contacted for
the 2008 report (EBMT survey). The non-European countries
affiliated with the EBMT were Algeria, Iran, Israel, Jordan,
Lebanon, Saudi Arabia, South Africa, and Tunisia. Thirty-
three teams in 16 countries (14 European and 2 affiliated
countries) reported novel cellular therapies using the survey
form, with detailed information on indication, cell source and
type, donor type, processing, and delivery mode. Additional
58 teams from 21 countries (19 European and 2 affiliated
countries) reported treatments using the standard EBMT ac-
tivity survey, allowing to include only limited information.
Responding teams are listed in the Appendix in alphabetical
order by country, city, and EBMT center code (if applicable),
along with the total numbers of reported cellular therapies.
According to the information received, there were no cellular
therapies (including HSC transplants) performed in Albania,
Andorra, Armenia, Georgia, Liechtenstein, Malta, Moldavia,
Monaco, Montenegro, San Marino, and The Vatican in 2008.
Transplant rates
Transplant rates, defined as numbers of cellular therapies
per 10 million inhabitants, were computed for each country,
without adjustments for patients who crossed borders or
received treatment in a foreign country. Population numbers
were obtained from the U.S. Census Office database (www
.census.gov).
Results
Number of novel cellular therapies
and disease indications
According to the received reports, a total of 1040 patients
were treated with novel cellular therapies, 376 (36%) with
allogeneic and 664 (64%)with autologous cells (Table 1). Main
indications were cardiovascular disorders (29%; 100% autol-
ogous), musculoskeletal disorders (18%; 97% autologous),
neurological disorders (9%; 39% autologous), epithelial dis-
orders (9%; 18% autologous), autoimmune diseases (12%;
77% autologous), and graft-versus-host disease (23%; 13%
autologous).
From 656 patients, more detailed informationwas obtained
concerning indications. Among the cardiovascular disorders,
myocardial ischemia (n¼ 185), bypass grafts (n¼ 43), and
cardiomyopathy (n¼ 13) were the most frequently reported
indications. Among the musculoskeletal disorders, cartilage
repair (n¼ 90) and bone repair (n¼ 24) were the main reason
for a cellular therapy. Skin reconstruction (n¼ 36) and liver
insufficiency (n¼ 11) were the two main reported indications
for epithelial/parenchymal disorders. Neurological indica-
tions only included unspecified disorders (n¼ 36). About
127 (19%) of all cellular therapies were for autoimmune dis-
orders; in this category, multiple sclerosis (n¼ 77) was the
leading subgroup, followed by other neurological indications
(n¼ 20).
Cell type, source, and donor type
Of the 406 HSC treatments, 84% were autologous trans-
plants and 70% were used to treat cardiovascular diseases
(Table 1). All 48 chondrocyte and 16 myoblast transplants
were autologous. Of the 491 mesenchymal stromal cell–
based therapies, 49% were allogeneic.
In the detailed survey, mesenchymal stromal cells were
obtained from bone marrow in all 251 cases and mostly used
to treat musculoskeletal (33%), neurological (12%), and au-
toimmune disorders (51%). For the 262 HSC treatments, cells
were derived from the bonemarrow (70%), placenta (3%), and
peripheral blood (27%). The donor type was associated with
the disease indication: autologous cells were used predomi-
nantly for cardiovascular (47%) and musculoskeletal (25%)
disorders, whereas allogeneic cells were used exclusively for
autoimmune (72%) and epithelial/parenchymal (28%) indi-
cations (Fig. 1).
Cell processing and delivery mode
Of all the grafted products reported in detailed form, 51%
were based on expanded cells and in 5% of the cases cells were
transduced (Table 2). About one-third (31%) of the products
was given intravenously, 45% intraorgan, 14% on a mem-
brane or gel, and 10% using a three-dimensional scaffold.
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Nonexpanded cells were used to treat 93% of cardiovascular,
50% of musculoskeletal, and 19% of neurological disorders,
whereas epithelial/parenchymal and autoimmune diseases
were exclusively treated with expanded cells. Beyond a few
sporadic exceptions, mostly reported for cardiovascular and
musculoskeletal diseases, transplanted cells were not geneti-
cally transduced or sorted.
For cardiovascular, neurological, and autoimmune appli-
cations, cells were delivered exclusively intravenous or in-
traorgan (Table 3). The use of a membrane or a gel for cell
FIG. 1. Percentage of indications for
novel cellular therapies in Europe 2008,
sorted by donor type. Data used for this
chart were derived only from the ex-
tended questionnaire.
Table 2. Number of Cellular Therapy Transplants for Novel Cellular Therapies
in Europe 2008 Sorted by Cell Processing Mode
Cell processing
Indications Nonexpanded Expanded Untransduced Transduced Unsorted Sorted
Cardiovascular
Peripheral artery disease 8 8 4 4
Cardiomyopathy 13 13 9 4
Heart failure
Myocardial ischemia 166 19 180 5 185
Bypass graft 43 43 43
Valve replacement
Decubitus ulcers
Other 13 13 13
Musculoskeletal
Bone repair (maxillofacial) 2 2 2
Bone repair (orthopedics) 21 1 22 20 2
Osteogenesis imperfecta
Cartilage repair 47 43 86 4 90
Muscle repair 2 2 2
Tendon/ligament
Reconstructive surgery 3 3 3
Other 22 22 22
Neurological
Parkinson’s
Peripheral nerve regeneration (trauma)
Other 7 29 36 36
Epithelial/parenchymal
Skin reconstruction 36 36 36
Cornea repair 4 4 4
Organ failure
Diabetes
Liver insufficiency 11 9 2 11
Other 39 39 39
Autoimmune
Neurological 20 20 20
Rheumatological 1 1 1
Gastrointestinal
Hematological 7 7 7
Multiple sclerosis 77 77 77
Other 22 22 22
Total 320 336 629 27 646 10
Data only from extended questionnaire.
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delivery was only reported for epithelial/parenchymal
treatments (12%) or for cartilage repair (2%). For the group of
musculoskeletal indications, all possible cell delivery modes
were reported, with a predominant tendency (46%) to use a
three-dimensional scaffold.
Cellular therapy rates
Reported cellular therapies were performed in a limited
number of countries and with different intensity. Figure 2
displays the cellular therapy rates per 10 million inhabitants
in the different European countries. High cellular therapy
rates were reported in Belgium, the Netherlands, Slovenia,
Switzerland, and Turkey.
Discussion
The study describes an extension of the previously consoli-
dated EBMT annual activity report, to cover the field of the
so-called ‘‘novel cellular therapies,’’ namely, the use of non-
hematopoietic cells or ofHSC for nonhematological indications.
The program is still at the experimental stage, and it clearly did
not include several teams active in the field of cellular therapy
in Europe. Despite this expected initial limit, the initiative
provided useful information on some of the trends related to
cell-based treatment of various diseases in 2008, which could
hardly be captured by analysis of scientific literature.
The survey does not include data on specific indications or
patient outcome, and thus the aims are clearly distinct form
those of a patient registry. Although the generated map does
not offer the possibility of a scientific analysis, the simple
structure of the platform and the absence of intellectual
property or commercial issues should encourage the contri-
bution by most academic and commercial groups. In this re-
gard, we deem as a remarkable outcome that already five
consolidated and large societies have joined forces toward the
establishment of the program.
Table 3. Number of Cellular Therapy Transplants for Novel Cellular
Therapies in Europe 2008 Sorted by Delivery Mode
Cell delivery mode
Intravenous Intraorgan Membrane/gel 3D scaffold Total
Cardiovascular
Peripheral artery disease 2 6 8
Cardiomyopathy 1 12 13
Heart failure
Myocardial ischemia 13 172 185
Bypass graft 26 17 43
Valve replacement
Decubitus ulcers
Other 13 13
Musculoskeletal
Bone repair (maxillofacial) 2 2
Bone repair (orthopaedics) 21 1 22
Osteogenesis imperfecta
Cartilage repair 12 14 64 90
Muscle repair 2 2
Tendon/ligament
Reconstructive surgery 3 3
Other 11 11 22
Neurological
Parkinson’s
Peripheral nerve regeneration (trauma)
Other 31 5 36
Epithelial/parenchymal
Skin reconstruction 36
Cornea repair 4 4
Organ failure
Diabetes
Liver insufficiency 11 11
Other 39 39
Autoimmune
Neurological 4 16 20
Rheumatological 1 1
Gastrointestinal
Hematological 7 7
Multiple sclerosis 62 15 77
Other 22 22
Total 204 294 93 65 656
Data only from extended questionnaire.
3D, three-dimensional.
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Overall, the presented data highlight a relatively large
activity in the clinical use of cell therapies, even in areas
where scientific data have not yet established a benefit for
the patient. To consolidate and further extend this initiative,
additional working groups will be invited to participate.
Moreover, it will be made more clear that reports for novel
cellular therapies will all have to be claimed using the de-
tailed form as opposed to the standard EBMT one. Next
year’s report, based on cell-based therapies performed in
2009, should thus more thoroughly capture the effective
patient numbers and the modes of cell processing and de-
livery. This European program is also expected to stimulate
parallel activities in other geographical areas, including the
North American, Asian-Pacific, and economically emerging
countries.
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APPENDIX
List of Reporting Novel Cellular Therapy Centers in Europe in 2008
Austria
Graz, Universita¨ts Kinderklinik, Ch. Urban (3; 3/0)a
Graz, University of Graz, W. Linkesch (4; 4/0)a
Vienna, St. Anna Kinderspital, H. Gadner, C. Peters (1; 1/0)a
Vienna, Medical University Hospital, S. Marlovitis (7; 0/7)
Belgium
Antwerpen, Suivenberg ZH, P. Zachee (3; 3/0)a
Antwerpen, Uiversity Antwerpen, W. Schroyens (1; 1/0)a
Brugge, A.Z. St. Jan, D. Selleslag, A.v. Hoof, J.v. Droogenbroeck, K.v. Eygen (2; 2/0)a
Brussels, Military Hospital Queen Astrid Gilbert Verbeken (72; 72/0)
Edegem, Center for Cellular Therapy and Regenerative Medicine, V. van Tendeloo (2; 1/1)
Leuven, University Hospital Gasthuisberg, G. Verhoef, M. Delforge, J. Maertens (5; 5/0)a
Lie`ge, University Hospital Sart-Tilman, Y. Be´guin, B. de Prijck (16; 16/0)a
Czech Republic
Olomouc, University Hospital, K. Indra`k (4; 0/4)a
Finland
Helsinki, Helsinki University Central Hospital, L. Volin (4; 0/4)a
Helsinki, Children’s Hospital, U. Pihkala, K. Vettenranta (1; 1/0)a
France
Clermont Ferrand, Centre Hospitalier Universitaire, Hoˆtel Dieu, F. Demeocq (14; 0/14)
Grenoble, Hospitalier A. Michallon, J.Y. Cahn, F. Garban, P. Drillat, D. Plantaz (1; 0/1)a
Grenoble, Saint Ismier, M.-J. Richard (1; 0/1)
Nancy, Vandoeuvre-les-Nancy, CHU Nancy-Brabois, P. Lederlin, F. Witz (5; 0/5)
Paris, Hopital St. Louis, J. Larghero (2; 0/2)
Poitiers, Hoˆpital Jean Bernard, La Miletrie, M. Renaud (1; 0/1)a
Germany
Berlin, Universita¨ts-Klinik Benjamin Franklin, E. Thiel, L. Uharek (8; 5/3)a
Darmstadt, Evangelisches Krankenhaus, Dr. Schreyer (4; 0/4)
Dresden, Universita¨tsklinikum Carl Gustav Carus, Med. Poliklinik, G. Ehninger, H. Bornha¨user (1; 0/1)
Dresden, Universita¨tsklinikum Carl Gustav Carus, Hematology, G. Ehninger, H. Bornha¨user (14; 14/0)a
Du¨sseldorf, Heinrich-Heine University, D. Dilloo, H.J. Laws, A. Borkhardt (1; 1/0)a
Frankfurt, Universita¨tsklinikum d. J.W. Goethe, T. Klingebiel, P. Bader (1; 1/0)a
Halle, Clinic Bergmannstrost, H.J. Meisel (7; 0/7)
Hamburg, Eppendorf-Krankenhaus, A.R. Zander, N. Kro¨ger (2; 2/0)a
Hannover, Medizinische Hochschule, A. Ganser, M. Eder (3; 3/0)a
Heidelberg, Universita¨ts-Poliklinik, A.D. Ho, P. Dreger (1; 1/0)a
Ko¨ln, Universita¨ts-Klinik, M. Hallek, Ch. Scheid, F. Berthold, T. Simon (3; 0/3)a
Tu¨bingen, Medizinische Universita¨ts-Klini (ads), L. Kanz, C. Faul (2; 2/0)a
Tu¨bingen, Medizinische Universita¨ts-Klinik (peds), R. Handgretinger, P. Lang (16; 16/0)a
Ulm, Kinderklinik der Universita¨t, W. Friedrich, K. Debatin (1; 1/0)a
Wiesbaden, Deutsche Klinik fu¨r Diagnostik, R. Schwerdtfeger, M. Schleuning (3; 3/0)a
Greece
Athens, Academy of Athens, A. Papassavas (30; 0/30)
Athens, Evanghelismos Hospital, D. Karakasis, N. Harhalakis, E. Nikiforakis (2; 2/0)a
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Athens, Aghia Sophia Children’s Hospital, S. Graphakos (4; 0/4)
Thessaloniki, The George Papanicolaou General Hospital, A.S. Fassas (2; 0/2)
Thessaloniki, Sports Clinic, Emanuel T. Papacostas (6; 0/6)
Iran, Islamic Rep.
Teheran, Shariati Hospital A. Ghavamzadeh (10; 0/10)
Teheran, Shariati Hospital A. Ghavamzadeh (25; 25/0)a
Israel
Jerusalem, Hadassah University Hospital, R. Or, S. Slavin (12; 12/0)a
Petach-Tikva, Beilinson Hospital, M. Yeshurun (1; 1/0)a
Italy
Bologna, 6th div Rizzoli Orthopedic Institute, S. Giannini, R. Buda (47; 0/47)
Firenze, Policlinico di Careggi, A. Bosi, S. Guidi (12; 0/12)
Monza, Ospedale S. Gerardo, C. Uderzo (2; 2/0)a
Pesaro, Ospedale San Salvatore, G. Visani (6; 6/0)a
Piacenza, Ospedale Civile, L. Capanna (6; 0/6)
Reggio di Calabria, Azienda Ospedale ‘‘Riuniti e Morelli’’, Bianchi-Melacrino, P. Iacopino (1; 0/1)
Roma, Universita` Cattolica, S. Cuore, S. Sica, G. Leone (1; 1/0)a
Torino, University Hospital, F. Fagioli, E. Vassallo (1; 1/0)a
Lebanon
Beirut, American University of Beirut, A. Bazarbachi (5; 0/5)
Netherlands
Leiden, University Hospital, R. Willemze, M. Egeler (48; 13/35)a
Nijmegen, University Hospital, A. Schattenberg, P. Hoogerbrugge (1; 0/1)a
Utrecht, University Hospital, L.F. Verdonck, N.M. Wulffraat (14; 0/14)
Utrecht, Erasmus University Medical Center, Wim J. van der Giessen (135; 0/135)
Norway
Oslo, University Hospital Rikshospitalet, J. Brinchmann (10; 0/10)
Poland
Cracow, University Children’s Hospital JUMC, J. Gozdzik (1; 1/0)a
Portugal
Lisbon, Instituto Portugues de Oncologia, M. Abecasis (4; 4/0)a
Russian Fed.
Moscow, Russian Children’s Hospital, A. Maschan, E. Skorobogato, E. Pachanov (7; 7/0)a
Moscow, Cancer Research centre, G. Mentrevich (59; 59/0)a
Moscow, Main Military Clinical Hospital, S.V. Shamansky, O.A. Rukavitcin (1; 0/1)a
Moscow, Research Haematology Center of RAS, V.G. Savtchenko (5; 5/0)
Novosibirsk, Inst. Clinical Immunolgy, I. Lisukov (19; 4/15)a
St. Petersburg, Trans-Technologies Inc., Andrey V. Krylov (144; 22/122)
St. Petersburg, Pavlov Medical University, B.V. Afanassiev, L. Zubarovskaya (14; 0/14)
St. Petersburg, Pavlov Medical University, B.V. Afanassiev, L. Zubarovskaya (14; 14/0)a
Serbia
Belgrade, Military Medical Academy, D. Stamatovic (7; 0/7)
Slovak Republic
Bratislava, National Cancer Institute, J. Lakota (1; 1/0)a
Slovenia
Ljublijana, University Medical Centre, J. Pretnar (10; 0/10)a
Ljublijana, Educell d.o.o, N. Kregar-Velikonja (14; 0/14)
Spain
Barcelona, Hospital Clinic, E. Carreras (2; 2/0)a
Cordoba, Hospital Reina Sofia, A. Torres-Gomez (16; 0/16)
Cruces-Barakaldo, Hospital de Cruces, I. Zuazua.Verde, F. Floristan (17; 0/17)a
Granada, Hospital Virgen de la Nieve, J.M. De Pablos Gallego, M. Jurado Chacon (1; 1/0)a
Madrid, Hospital de la Princesa, A. Figuera, A. Alegre (7; 0/7)a
Madrid, Hospital La Paz, A. Martinez, A. Sastre, R. Arrieta (3; ½)a
Madrid, Hospital General Universitario Gregorio Maranon, J.L. Diez-Martin (1; 1/0)a
Murcia, Hospital Virgen de la Arrixaca, J.M. Moraleda, A. Morales Lazaro (10; 0/10)
Palma de Mallorca, Hospital Son Dureta, J. Besalduch, M. Canaro (6; 6/0)a
Pamplona, Clinica Universitaria de Navarra, J. Rifon (21; 1/20)
Salamanca, Complejo Hospital, D. Caballero (11; 11/0)a
Sweden
Lund, University Hospital, S. Lenhoff (2; 2/0)a
Stockholm, Karolinska University Hospital, Huddinge, P. Ljungman (5; 5/0)a
Switzerland
Geneva, Hoˆpital Cantonal Universitarie, J. Passweg, Y. Chalandon (8; 1/7)a
Lugano, Cardiocentro Ticino, G. Astori (26; 0/26)
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Turkey
Adana, Baskent University Adana, H. Ozdogu, C. Boga (2; 2/0)
Ankara, Ihsan Dogramaci Children’s Hospital (Hacettepe), A. Tuncer, D. Uckan (1; 1/0)a
United Kingdom
Cambridge, Addenbrooke’s Hospital, C. Crawley, R.E. Marcus, J. Craig (2; 2/0)a
Leeds, St. James’s University HospitalþThe General Infirmary, M. Gilleece, S. Kinsey (2; 2/0)a
Format: city, hospital, physician (total treatments; allogeneic/autologous).
aNumbers and teams were imported from the limited questionnaire included in the standard European Group for Blood and Marrow
Transplantation survey sheet.
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